Stockscreener 앱 받기
11.34
1.05%
-0.1131
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch & Lomb Corp (BLCO) Trading Down 3.41% on May 30 - GuruFocus
Cetera Investment Advisers Decreases Stock Holdings in Bausch + Lomb Co. (NYSE:BLCO) - Defense World
Public market insider buying at Bausch + Lomb (BLCO) - The Globe and Mail
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch + Lomb’s SWOT analysis: stock outlook amid market challenges - Investing.com
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference - BioSpace
Bausch & Lomb shareholders approve board nominees and compensation - Investing.com
Bausch + Lomb shareholders elect 10 directors at annual meeting By Investing.com - Investing.com India
Bausch + Lomb shareholders elect 10 directors at annual meeting - Investing.com
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results - Yahoo Finance
Bausch + Lomb (BLCO) Launches LUMIFY Preservative Free Eye Drops in the U.S. | BLCO Stock News - GuruFocus
Global Intraocular Lens Market to Witness Upsurge in Growth at a CAGR of ~5% by 2032 | DelveInsight - GlobeNewswire Inc.
Bausch + Lomb introduces Zenlens CHROMA HOA lenses By Investing.com - Investing.com Canada
Bausch + Lomb introduces Zenlens CHROMA HOA lenses - Investing.com
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States - The Joplin Globe
BLCO Q1 Earnings Call: Misses on Profit, Highlights Product Innovation and Tariff Uncertainty - Yahoo Finance
Bausch + Lomb Co. (NYSE:BLCO) Given Average Recommendation of “Hold” by Analysts - Defense World
Morgan Stanley Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $12.00 - Defense World
Bausch + Lomb’s LuxLife Intraocular Lens Gains European CE Mark Approval - TipRanks
Bausch + Lomb (BLCO) Receives CE Mark for LuxLife Intraocular Lens | BLCO Stock News - GuruFocus
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens - Stock Titan
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BLCO Stock News - GuruFocus
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BL - GuruFocus
20,600 Shares in Bausch + Lomb Co. (NYSE:BLCO) Bought by Renaissance Technologies LLC - Defense World
Citigroup Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwr - GuruFocus
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Price Target | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Evercore ISI Group - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Wells Fargo | BLCO Stock News - GuruFocus
Bausch + Lomb Corporation (NYSE:BLCO) Q1 2025 Earnings Call Transcript - Insider Monkey
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Press - GuruFocus
Bausch + Lomb (BLCO) Sees Adjusted Price Target Amidst Earnings Update | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectati - GuruFocus
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Pressures | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Citi After Q1 Repor - GuruFocus
Bausch & Lomb Earnings: Amid Tariff and Recall Concerns, Shares Sink on Shaky Start to 2025 - Morningstar
Bausch + Lomb (BLCO) Misses Revenue Expectations in Q1, Shares D - GuruFocus
Bausch + Lomb (BLCO) Misses Q1 Estimates, Lowers Growth Outlook - GuruFocus
Bausch & Lomb Reports Weak Start to 2025 as enVista Recall, Tariffs, and Drug Pricing Cause Concerns - Morningstar
Bausch & Lomb Corp SEC 10-Q Report - TradingView
Bausch + Lomb stock hits 52-week low at $10.46 By Investing.com - Investing.com India
Bausch + Lomb stock hits 52-week low at $10.46 - Investing.com Australia
Bausch + Lomb shares tumble as Q1 earnings miss expectations By Investing.com - Investing.com Canada
Bausch + Lomb shares tumble as Q1 earnings miss expectations - Investing.com
Bausch + Lomb Announces First-Quarter 2025 Results - BioSpace
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Bausch + Lomb Reports Q1 2025 Revenue Growth Amid Challenges - TipRanks
Bausch + Lomb Q1 2025 slides: Revenue grows 5% despite enVista recall impact - Investing.com
Bausch + Lomb (BLCO) Updates FY25 Financial Outlook | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectations | BLCO Stock News - GuruFocus
Bausch + Lomb: Q1 Earnings Snapshot - Barchart.com
Bausch + Lomb Q1 2025 Financial Results - TradingView
0.75%
0.84%
자본화:
|
볼륨(24시간):